hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

GlaxoSmithKline, AstraZeneca, Merck, Pfizer & other firms join UK govt. in committing to increased access to essential medicines for poorest countries, including via differential pricing

Get RSS feed of these results

All components of this story

30 March 2005

Renewed Commitment to Government – Industry Partnership to Improve Access to Medicines

Author: UK Department for International Development (DFID)

The UK Government and the world’s largest pharmaceutical companies today committed to continue to work together to help increase access to essential medicines for the world’s poorest countries...The UK Government’s framework for good practice has been developed with the support and input of the pharmaceutical industry, including GlaxoSmithKline (GSK), AstraZeneca, Merck & Co., Inc., Pfizer, the Association of the British Pharmaceutical Industry (ABPI) and the American Pharmaceutical Group (APG)...[which] represents eleven US pharmaceutical companies, including Abbott Laboratories, Amgen, Bristol-Myers Squibb, Chiron Vaccines, Janssen-Cilag Ltd [part of Johnson & Johnson], Lilly [Eli Lilly], Merck Sharp & Dohme, Pfizer, Procter & Gamble Pharmaceuticals, Schering-Plough and Wyeth Pharmaceuticals.

Read the full post here

1 March 2005

[PDF] Increasing people’s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry

Author: UK Department for International Development (DFID)

Responsibility for increasing access to essential medicines rests with the whole international community...In this context there is a particular role for pharmaceutical companies. As the producers of existing, and developers of new, medicines they can – and do – make a difference within their sphere of influence. [refers to Novartis, GlaxoSmithKline, Merck, Roche, Ranbaxy Laboratories, AstraZeneca, Tibotec (part of Johnson & Johnson), Eli Lilly, Pfizer, Shire Pharmaceuticals]

Read the full post here